Lukas Biomedical Inc. (TPEX:6814)
Taiwan · Delayed Price · Currency is TWD 23.90
-1.05 (-4.21%)
May 29, 2026, 1:21 PM CST
Lukas Biomedical Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -85.63 | -94.38 | -47.35 | -50.07 | -49.49 |
Depreciation & Amortization | 25 | 28.52 | 31.57 | 35.96 | 42.73 |
Other Amortization | 0.03 | 0.03 | 0.06 | 0.11 | 0.33 |
Loss (Gain) From Sale of Assets | -0.02 | - | 0.47 | -1.02 | 1.21 |
Stock-Based Compensation | - | 0.07 | - | - | 0.17 |
Provision & Write-off of Bad Debts | 0.01 | 0.2 | -0 | -0.1 | -1.19 |
Other Operating Activities | 1.96 | -0.06 | -0.39 | -0.05 | -0.14 |
Change in Accounts Receivable | -1.85 | 0.8 | 1.41 | 6.27 | 7.26 |
Change in Inventory | 2.64 | -1.3 | 5.68 | -15.51 | -9.24 |
Change in Accounts Payable | -1.59 | -1.25 | -2.03 | 5.8 | 1.18 |
Change in Unearned Revenue | -0.54 | 0.07 | -10.18 | 10.49 | 0.21 |
Change in Other Net Operating Assets | -1.44 | -3.24 | 9.02 | 0.69 | -9.19 |
Operating Cash Flow | -61.43 | -70.54 | -11.75 | -7.44 | -16.16 |
Capital Expenditures | -8.22 | -6.81 | -2.66 | -2.98 | -10.03 |
Sale of Property, Plant & Equipment | 0.02 | - | - | - | - |
Sale (Purchase) of Intangibles | -0.31 | - | - | - | - |
Investment in Securities | - | -1.81 | - | - | - |
Other Investing Activities | -0.13 | -1.17 | 1 | 5.84 | -0.3 |
Investing Cash Flow | -8.64 | -9.79 | -1.66 | 2.87 | -10.33 |
Short-Term Debt Issued | 65 | - | 5 | - | 30 |
Long-Term Debt Issued | - | - | 20 | - | - |
Total Debt Issued | 65 | - | 25 | - | 30 |
Short-Term Debt Repaid | - | -5 | - | -90 | - |
Long-Term Debt Repaid | -24.9 | -21.65 | -20.29 | -20.34 | -22.38 |
Total Debt Repaid | -24.9 | -26.65 | -20.29 | -110.34 | -22.38 |
Net Debt Issued (Repaid) | 40.1 | -26.65 | 4.71 | -110.34 | 7.62 |
Issuance of Common Stock | - | 140 | - | 90.88 | 45.12 |
Other Financing Activities | -0.01 | -0.11 | 0.23 | -0.52 | -0.49 |
Financing Cash Flow | 40.1 | 113.24 | 4.94 | -19.98 | 52.25 |
Net Cash Flow | -29.97 | 32.91 | -8.46 | -24.55 | 25.77 |
Free Cash Flow | -69.64 | -77.35 | -14.41 | -10.41 | -26.18 |
Free Cash Flow Margin | -38.80% | -40.75% | -6.21% | -5.63% | -16.61% |
Free Cash Flow Per Share | -1.66 | -1.95 | -0.39 | -0.28 | -0.80 |
Cash Interest Paid | 3.1 | 2.97 | 2.85 | 2.92 | 4.42 |
Cash Income Tax Paid | 0.01 | 0.03 | 0.01 | - | 0.66 |
Levered Free Cash Flow | -38.96 | -41.56 | 3.71 | 8.55 | -8.11 |
Unlevered Free Cash Flow | -36.95 | -39.66 | 5.63 | 10.37 | -5.35 |
Change in Working Capital | -2.79 | -4.92 | 3.9 | 7.74 | -9.78 |